

1 **Jefferson Office of Human Research**
2 **Informed Consent OHR-8**
3 **Version Date – FOR OHR USE: 12/7/21**

4
5 **Department:** Center for Neurorestoration

6
7 **Principal Investigators:** Jayakrishnan Nair, PT, MSPT, PhD, Mijail Serruya,
8 MD, PhD

9
10 **Study Title: Motor Restoration in Chronic SCI with Combinatorial**
11 **Intermittent Hypercapnic-Hypoxia and Transcutaneous Spinal**
12 **Stimulation**

13
14 **Lay Title: Combination Therapy with Therapeutic Air Mixture and**
15 **Electrical Stimulation on the Neck**

16
17 **General Information Section**

18
19 **Informed Consent**

20
21 You are being asked to take part in a research study. Research is different
22 from standard medical care, and is done to learn something new.

23
24 Please read on to find out:

25
26 • The purpose of this research.
27 • How this research is different from standard medical care.
28 • The procedures involved.
29 • The risks.
30 • The possible benefits.
31 • The alternatives to taking part in this research.

32
33 You will have the opportunity to discuss this study with the research
34 personnel. Use this information to decide if you want to take part in this
35 research. This process is called informed consent.

36
37 **Voluntary Participation**

38
39 You do not have to take part in this research. It is your choice whether or not
40 you want to take part. If you choose not to take part or choose to stop taking
41 part at any time, there will be no penalty or loss of benefits that you would
42 normally get.

44 **Purpose**

45
46 You are being asked to participate in this research study because you have
47 complete or partial paralysis due to a spinal cord injury (SCI). Paralysis
48 means that you are unable to move your arms, legs, hands or feet or you
49 have reduced use of them. The therapeutic air mixture and the study devices
50 may help with loss of strength, function or with complications of paralysis,
51 but there is not a guarantee that being in this study will help you.

52
53 The goal of this study is to evaluate if short bouts of breathing low oxygen with
54 elevated carbon-dioxide separated by breathing normal air combined with
55 non-invasive electrical spinal cord stimulation can help people with SCI
56 to improve strength and function of muscles involved in breathing and hand
57 function. The technical name of this breathing approach is called “acute
58 intermittent hypercapnic-hypoxia” or AIHH.

59
60 The study will involve five (5) visits. Each session will last up to four hours.
61 Each session will be scheduled on a separate day, with at least one week in
62 between, hence over a minimum of four weeks. Sessions involving
63 exposure to therapeutic air (AIHH) followed by a short 20-30 min rest break.
64 After the rest break you will be asked to wear a noninvasive spinal electrical
65 stimulation device and perform occupational and/or physical therapy with
66 the spinal stimulator turned on.

67
68 Breathing the therapeutic air (AIHH) has previously been shown to improve
69 breathing health and hand strength. This appears to happen because it causes
70 nerve cells to build stronger connections with each other. This approach might
71 help people who have respiratory and hand weakness. The electrical energy is
72 delivered through surface electrodes placed on the skin, and is thought to
73 enable the spinal cord and nerves to become active again. Studies in animals
74 and humans suggest that improvements in hand and/or arm function and
75 other types of functional recovery might occur with AIHH as well as
76 electrical stimulation.

77
78 **How this Research is Different from Standard Medical Care**

79
80 This study will not include any standard of care procedures. This study is novel
81 because it combines two experimental therapies i.e. AIHH and non invasive
82 spinal electrical stimulation for improvement of function in muscles involved
83 in breathing and hand function. This study will also explore why some
84 individuals respond well and some do not.

85 As a part of this study, you will receive Physical therapy/Occupational therapy
86 exercise based intervention which is standard of care for patients with SCI. In
87 addition, you will receive an experimental gas mixture followed by electrical

88 stimulation on the neck. Both of these interventions are not part of standard
89 of care. The novel non-invasive spinal electrical stimulation used in this study
90 may feel similar to transcutaneous nerve stimulation (TENS) and functional
91 electrical stimulation (FES) that are routinely performed as standard of care
92 for SCI in Physical therapy. Unique to this study, you may undergo up to a
93 maximum of two blood tests and one-time saliva collection

94

95 **Number of Participants**

96

97 In total, 29 participants will be recruited in this part of the study.

98

99 **Duration**

100

101 This study involves a minimum of 5 separate visits to the laboratory. The first
102 visit will be screening, where the study physician will assess your safety and
103 Physical/Occupational therapist will determine if you meet the inclusion
104 criteria, followed by mapping of muscle response to magnetic and electrical
105 stimulation of your brain and nerves. Once you qualify for the study, you will be
106 asked to visit the laboratory on a minimum of 4 separate testing days, inter-
107 spaced with a minimum of 1 week washout period. Testing on all 4 sessions
108 will last for up to 4 hours. The total expected time requirement, therefore, is
109 approximately 16 hours, following the screening visit. If a testing session is
110 delayed due to equipment malfunction or other unexpected delays, testing
111 may take longer. If such a delay were to occur, you may be asked to either
112 stay longer than 4 hours (up to a maximum of 5 hours), and/or you may be
113 asked to return for an additional session beyond the original 4 (up to 6
114 sessions).

115

116 **Procedures and Risks**

117 It is important that you know the procedures and risks involved in this research.
118 These will be discussed with you and are included in detail later in this form.
119 Review the information carefully when making your decision to take part in
120 this research.

121

122 **Possible Benefits**

123 You may or may not personally benefit from taking part in this research.
124 Benefits may include helping improve paralysis and some conditions related
125 to paralysis. In addition, it may improve your function. Your state of paralysis
126 might not get better while you are in this study. Information from this study
127 might help researchers to better understand how to treat paralysis.

129 **Alternatives to Taking Part in this Research**

130

131 You have other options than taking part in this study. Participating in physical
132 and/or occupational
133 therapy with or without functional electrical stimulation is an alternative way
134 to continue to work toward making functional progress after your spinal cord
135 injury. The alternative to being in this study is to not take part. You may discuss
136 alternatives to participating in this research with study
137 staff or with your regular health care provider.

138

139 **Costs**

140

141 There will be no study related cost to you. If you receive a bill that you think is incorrect,
142 please contact the research personnel. There is no plan to pay you for lost wages, lost time from
143 work, personal discomfort, or for injuries or problems related to your underlying medical condition.
144 As stated in the next section on Payment, you will be paid for attending sessions. You may use that
145 Payment to pay for travel and parking if you wish.

146

147

148 **Payment**

149

150 All participants are expected to be within the local Philadelphia area; therefore no hotel or airfare
151 reimbursement will be permitted. The estimated travel costs are as follows:
152 Participants will be reimbursed up to \$50 for each test visit and \$25 for screening visit.
153 Mileage reimbursement will be at the government 2022 rate of \$0.56 per mile.
154 Parking will be reimbursed and may require the use of a TJU voucher.
155 The maximum amount of parking-and-travel cost per person will be \$50 per visit.
156 All payments from Jefferson will be in the form of a ClinCard, a kind of debit card that you can
157 use to pay for any type of product or service just as you would use a regular debit or gift card.

158

159 **Ending Study Early**

160

161 There are a number of reasons you may decide or be asked to stop the study
162 early (example: medical issues). You may also have to stop the study early
163 even if you do not want to. You and the research personnel will discuss the
164 reason if this becomes necessary. If you do leave the study early, you may be
165 asked to complete some of the procedures described in this form.

166

167 **New Information**

168

169 New information may come out during this study. You will be given any new
170 information that could change your decision to take part. You may ask to see
171 the information collected about you, but not until the entire study is complete.
172 You will be given any research results that could affect your health.

173

174 **Detailed Information Section**

175
176

Procedures

177
178
179
180

While you are in this study, you will undergo different procedures which are described below. Please note that additional tests and procedures may be needed to check on your health condition.

181
182
183
184
185
186
187
188

This study consists of four (4) intervention visits and one (1) baseline assessment visit, with at least 1 week interval between sessions. During sessions, you will be asked basic questions about you and your health and then undergo exposure to therapeutic air mixture (AIHH), non-invasive electrical stimulation, and functional testing. In addition, up to 10 ml blood will be drawn at the beginning of combinatorial treatment session and saliva sample will be collected once.

189
190
191
192

1. Box & Blocks and Pinch and Grip Force Assessments: These functional tests will measure your strength and ability to use your upper extremity and hand.

193
194
195
196
197
198
199
200
201

2. Maximum inspiratory pressure: You will be asked to exhale completely and attempt a maximal inhalation through a mouthpiece for at least 2 seconds against resistance. The mouthpiece connected to a pressure transducer will record the amount of force you can generate to inspire air.

3. Mouth occlusion pressure: This measure will be obtained while you breathe through a mouthpiece connected to a 2-way valve in a closed circuit. The valve through which you will be inhaling air will be momentarily occluded without your awareness, after you have expired air, until the next breath.

202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217

4. Magnetic stimulation (cervical, CMS and transcranial, TMS) and electrical nerve conduction study: CMS, TMS, and electrical nerve conduction studies are safe and non-invasive nerve stimulation techniques that have been used in clinical and research settings for over 30 years. We will perform a series of magnetic stimulations on top of your head (known as transcranial magnetic stimulation) and over the back of your neck (known as cervical magnetic stimulation) or in your forearm and hand in order to activate the phrenic nerve that innervates the diaphragm and/or hand muscles. These procedures are commonly used in research and are well-established. During these stimulations, we will record electrical activity of the diaphragm muscle using surface electrodes placed on the chest wall over your ribs. We will then record your resting breathing and monitor cardiovascular variables like heart rate and blood pressure. You will then breathe a predetermined gas concentration for approximately 30 minutes while we record breathing and cardiovascular responses. We will continue to

218 monitor these readings for up to 1 hour after exposure. We will then
219 perform a final set of magnetic stimulations to compare with baseline.

219 **5. Surface electromyography (EMG):** EMG will be conducted to record the
220 activation of breathing muscles during the respiratory tests. By analyzing
221 the electrical activity generated during a muscle contraction, EMG
222 analyses allow us to understand timing and amplitude of muscle
223 activation as well as the frequency content of the EMG signal. Using a
224 standard surface preparation (cleaning the skin with water or alcohol pad,
225 shaving of excess hair) and electrode placement, EMGs will be collected
226 from your muscles involved in inspiring air using surface EMG electrodes.
227 EMG sensors will be attached to the skin with hypoallergenic medical
228 tape. Before data is collected we will check to ensure that the quality of
229 EMG signal is free from noise and interference. The electrode gel used
230 during electrode placement is slightly abrasive and may cause skin
231 irritation. We encourage you to inform the researcher of any skin
232 conditions and discomfort during electrode placement.

233 **6. RT Xcite device:** This device uses electrical stimulation, which is a form
234 of electrical energy that passes through your skin and the tissue below
235 your skin, such as your fat and muscles, down to the nerves and nerve
236 cells that make up your spinal cord. The type of electrical energy being
237 used is thought to enable the spinal cord and nerves to become active
238 again after an injury or illness which has caused paralysis. Studies in
239 animals and humans suggest that improvements in hand and/or arm
240 function and other types of functional recovery might occur with this
241 type of stimulation. The device uses gel electrodes that are placed on
242 your skin. These electrodes will be placed on specific locations on the
243 skin of your neck and/or back and will be connected to a
244 stimulator. The electrodes have a hydrogel sticky surface; so if you
245 have an allergy to any type of gel or adhesive material, please inform the
246 study staff.

247 **7. Respiratory resistance training:** This intervention will involve using a
248 special mouthpiece to provide resistance when you are inspiring
249 (breathing in) or expiring (breathing out) air from the room around you.
250 You will be asked to breathe against resistance that will be based on your
251 own individual respiratory strength (determined prior to starting the
252 intervention). You will be asked to complete three training sets of
253 approximately 6-12 repetitions of *breathing in* and three training sets
254 of approximately 6-12 repetitions of *breathing out*. You will be given short
255 rest periods of about 10-15 seconds of normal breathing between
256 repetitions. We will monitor your heart rate and blood pressure at regular
257 intervals. You may take longer rest periods if needed.

258 **8. Functional strength training:** you may be asked to perform motions
259 Of different parts of your body, to the best of your ability. This practice
260 will be familiar to you, as it will be exactly what is done in traditional,

261 standard-of-care occupational and physical therapy; and it will be
262 performed with a certified occupational or physical therapist. You will
263 be given rest periods following the same guidelines that therapists
264 typically use in outpatient rehabilitation. We will monitor your heart rate
265 and blood pressure at regular intervals. You may take longer rest
266 periods if necessary.

267 **9. Blood Draws:** Following completion of the initial paperwork, you will be
268 asked for a blood draw. A registered nurse/phlebotomist will collect 10 ml
269 of blood which is roughly equal to 2 teaspoons. The blood sample will be
270 collected from your arm by inserting a small needle. Your blood will be
271 drawn only once, which is during the first intervention session. It will be
272 stored in a secured location with your coded study ID until the end of the
273 study. After the study is over the sample will be destroyed and discarded.

274 **10. Saliva Collection:** At one time point during your five research
275 visits, you will be asked to submit 2ml of saliva by spitting into a
276 sterile container. The collected saliva will be processed and analyzed to
277 determine if you respond *or not* to treatment based on your individual
278 genetic differences. The saliva will be collected only once and stored in
279 a secured location with your coded study ID until the end of the study.
280 After the study is over the sample will be destroyed and discarded.

282 **11. Blinding:** Participants and blinded assessors will be made aware of
283 possible air mixtures, but not made aware of the intervention delivered.
284 Based upon reports from participants (N=6) blinded during prior study
285 (Hayes et al., 2014), 4 of 6 guessed incorrectly or were uncertain of the
286 Acute Intermittent Hypoxia (AIH) intervention received, suggesting our
287 prior blinding and air delivery methods were effective; similar
288 uncertainty was reported in all published trials in humans with SCI.
289 However, participants receiving AIHH intervention with elevated CO₂
290 pressure are likely to experience mild levels of dyspnea/ air hunger and
291 are therefore more likely to correctly guess the intervention. Regardless,
292 we will rigorously monitor and quantify blinding integrity by asking
293 blinded participants and assessors to guess the intervention received at
294 the end of each intervention and to indicate guess confidence using a
295 Likert scale (Likert, 1932; Brunoni et al., 2014). We will use a
296 contingency table and Fischer's Exact Test to determine if the
297 probability of correct guessing is different from chance.

299 Risks

300 Taking part in this study involves certain risks. There may also be risks that
301 are not known at this time. If you have any medical issues during this study,
302 call the appropriate number in the contacts section of this form.

303 **AIHH and Respiratory and Hand Muscle Strength training:** The risks associated
304 with AIHH and respiratory strength training are minimal and the lower
305 oxygen levels associated with AIHH have been shown to be easily tolerated
306 without discomfort or negative responses. Specifically, many studies have
307 shown that AIHH at the levels and dosage used in this study, and respiratory
308 or hand muscle strength training can be delivered safely, with no adverse
309 events.

310 Furthermore, we will work to ensure your safety and comfort throughout all of
311 the study procedures. We will ask you questions regularly to monitor your
312 general health, such as questions about your pain, spasticity, medication-use,
313 or sleep. You will be asked to let us know if you have any dizziness, headache,
314 vision changes, or any other feeling of discomfort throughout the study. We
315 encourage you to let the study staff know about your comfort and how you are
316 feeling throughout all study procedures to ensure your safety and comfort.
317 A licensed clinician with experience working with individuals with spinal cord
318 injuries will oversee all participant testing and interventions. You will complete
319 the study procedures while seated or lying down in a safe and supported
320 manner and your responses to testing and interventions will be observed
321 closely. Additionally, you will be allowed to take rest breaks as often as
322 needed.

323
324 Common discomforts that may occur in this study and steps to alleviate them
325 are:

326 1) The mask used to deliver the low and higher level oxygen mixtures may be
327 uncomfortable. The fit and placement of the mask will be adjusted as
328 necessary to ensure maximum comfort. Additionally, the mask will be removed
329 during periods of breathing normal room air to give you a break from wearing
330 the mask.

331 2) You may feel sleepy during delivery of either gas mixture. This may be due
332 to breathing low-oxygen air, or due to sitting still in a reclined position. Feelings
333 of sleepiness typically last only for the duration of the intervention. Both gas
334 mixtures will be delivered while you are seated in a semi-reclined position with
335 head, arm, and feet support as necessary for comfort, and to ensure safety.
336 Additionally, study staff will talk with you throughout the interventions to keep
337 you engaged and encourage you to stay awake.

338 3) You may feel slight discomfort and/or fatigue during or shortly after bouts
339 of respiratory strength training due to the effort involved in completing the
340 training. You will be provided as much rest as necessary in between sets of
341 training exercises to lessen any fatigue. Heart rate, blood oxygen saturation,
342 and blood pressure will be continuously monitored throughout respiratory
343 strength training to ensure that you are not over-exerting yourself during the
344 training.

345 Rare but possible risks in this study and steps to alleviate them are:

346 1) Breathing low levels of oxygen and slightly elevated carbon-dioxide
347 (during AIHH) causes low levels of oxygen and high levels of carbon-dioxide in
348 the blood. Side effects of low blood oxygen levels can include lightheaded
349 sensations, dizziness, reduced vision, or euphoria. If you report any of these,
350 or other general discomfort during the low-oxygen intervals, delivery of AIHH
351 will be terminated. The effects of breathing intermittent low levels of oxygen
352 are well-studied in humans and methods proposed here are deemed safe. Our
353 mild AIHH dose is based on human studies that delivered AIHH without
354 unwanted side effects.

355 2) Significant sudden increases or decreases in heart rate, respiratory rate,
356 or blood pressure may be signs of an adverse response to study procedures.
357 To minimize risks from sudden increases or decreases in heart rate, respiratory
358 rate, or blood pressure, these vital signs will be monitored throughout all study
359 procedures. In the event that one or more of them shows a sudden change,
360 study procedures will be stopped. Your vitals will be monitored by study staff.
361 If you report additional discomfort or the vitals do not return to baseline in a
362 time deemed safe by study staff, the study physician and principal investigator
363 will be notified and/or, if necessary, emergency medical services will be
364 contacted.

365 3) Reproductive risks--Because the treatment in this study might affect an
366 unborn baby, you should not become pregnant while in this study. Since this
367 treatment will not be given to any patients who are pregnant, all women of
368 childbearing potential must take a pregnancy test prior to receiving any
369 treatment on this study. We encourage all women enrolled on this study to
370 use one of the effective birth control methods while enrolled in this study.
371 These methods include total abstinence (no sexual intercourse), oral
372 contraceptives ("the pill"), an intrauterine device (IUD), an etonogestrel
373 implant (Implanon), or medroxyprogesterone acetate injections (Depo-Provera
374 shots). If one of these cannot be used, using contraceptive foam and a condom
375 are recommended. You must notify the study staff if you become pregnant
376 during the course of the study.

377 4) During muscle activity recording (surface electromyography) adhesive
378 from the disposable stickers might be uncomfortable when peeled off hairy
379 skin. Hair may be shaved from the skin prior to placement of electrodes to
380 avoid discomfort when removing.

381 382 Risks associated with noninvasive spinal cord stimulation: Skin surface
383 electrical stimulation via hydrogel electrodes is known to commonly cause
384 minor discomfort during or after stimulation. Skin irritation or redness from the
385 electrodes. Muscle or joint stiffness, discomfort, strain and spasms. Some
386 uncommon side effects include dizziness, allergic reaction to electrodes,
387 bruising from being positioned, lower or elevated blood pressure, increased
388 heart rate, shortness of breath, pain or discomfort. Rarely, burns to the skin
389 from electrodes, bone fractures during exercise training have also been reported.

390
391 **Risk associated with magnetic stimulation:** Single-pulse transcranial magnetic
392 stimulation is generally considered safe. However, there is a very low risk of
393 seizure. Therefore, you should not participate if you have any history of seizures
394 or epilepsy. Due to the magnetic field, your arms and shoulders may move
395 during the stimulation and may experience shoulder and/or neck ache. There is
396 a loud sound from the stimulation machine that may be startling but is not
397 dangerous.

398 **Magnetic stimulation (cervical and transcranial)** is a safe and non-invasive
399 nerve stimulation technique that has been used in clinical and research
400 settings for over 30 years. The risks associated with magnetic stimulation are
401 minimal; however, you may feel discomfort during the stimulations, including
402 shoulder or neck ache for cervical stimulations. If you are uncomfortable with
403 the higher intensities of stimulation, please let your study team know
404 and extended breaks will be given, or if desired, no further stimulations will
405 be performed. Using single-pulse TMS, even the highest stimulation setting is
406 not harmful. There is a clicking sound that may be startling but is not
407 dangerous. Although rare, seizures are a potential side effect of single-pulse
408 TMS. In the event of a seizure or other medical emergency, emergency
409 services (911) will be called.

410
411 Additionally, researchers will take appropriate steps to protect any information
412 they collect about you. All data collected will be stored in secured locations
413 such as a locked filing cabinets, on secured, password-protected computer
414 servers, or on encrypted electronic storage devices. However, there is a slight
415 risk that information about you could be revealed inappropriately or
416 accidentally. Depending on the nature of the information, such a release could
417 upset or embarrass you, or possibly affect your ability to be insured or
418 employed. Questions 8 and 9 in this form discuss what information about you
419 will be collected, used, protected, and shared.

420
421 This Research Study may also include risks that are unknown at this time.
422 Please note, participating in more than one research study or project may
423 further increase the risks to you. If you are already enrolled in a research
424 study, please inform one of the Research Team members or the person
425 reviewing this consent with you before enrolling in this or any other research
426 study or project.

427
428 During the study, the Research Team will notify you of new information that
429 may become available and might affect your decision to remain in the study.

430
431 The Thomas Jefferson University is required by law to protect your health
432 information. Your health information will be stored in locked filing cabinets or
433 on computer servers with secure passwords, or encrypted electronic storage
434 devices, as required by University policy. However, there is a slight risk that

435 information about you could be released inappropriately or accidentally.
436 Depending on the type of information, a release could upset or embarrass you,
437 or possibly affect your ability to get insurance or a job.

438

439 A new Federal law, called the Genetic Information Nondiscrimination Act
440 (GINA), generally makes it illegal for health insurance companies, group health
441 plans, and most employers to discriminate against you based on your genetic
442 information. This law generally will protect you in the following ways:

443

- 444 • Health insurance companies and group health plans may not request
445 your genetic information that we get from this research.
- 446 • Health insurance companies and group health plans may not use your
447 genetic information when making decisions regarding your eligibility or
448 premiums.
- 449 • Employers with 15 or more employees may not use your genetic
450 information that we get from this research when making a decision to hire,
451 promote, or fire you or when setting the terms of your employment.

452

453 All health insurance companies, and group health plans must follow this law
454 by May 21, 2010. All employers with 15 or more employees must follow this
455 law as of November 21, 2009. Be aware that this new Federal law does not
456 protect you against genetic discrimination by companies that sell life
457 insurance, disability insurance, or long-term care insurance.

458

459 To help us protect your privacy, we have obtained a Certificate of
460 Confidentiality from the National Institutes of Health. With this Certificate, the
461 researchers cannot be forced to disclose information that may identify you,
462 even by a court subpoena, in any federal, state, or local civil, criminal,
463 administrative, legislative, or other proceedings. The researchers will use the
464 Certificate to resist any demands for information that would identify you,
465 except as explained below.

466

467 The Certificate cannot be used to resist a demand for information from
468 personnel of the United States Government that is used for auditing or
469 evaluation of federally funded projects or for information that must be
470 disclosed in order to meet the requirements of the federal Food and Drug
471 Administration (FDA).

472

473

474 Risks of Blood Draw

475 For most people, having blood taken is quick, easy and relatively painless.
476 Other people may feel anxious and occasionally the participant may feel
477 unwell or faint. Therefore, you will be asked to stay under study staff
478 supervision until you fully recover after a blood draw. Some people have a

479 tendency to bruise at the site of venipuncture. In order to prevent, a cotton-
480 wool dressing will be taped over the puncture site and you will also be asked
481 to avoid carrying anything heavy or undertake strenuous exercise within 24
482 hours of the blood sample collection.

483

484

485 **Strength testing risks**

486 Your hand and breathing muscles can develop temporary soreness following
487 muscle strength testing. Any muscle soreness related to muscle testing should
488 subside within 24 to 48 hours. If muscle pain persist longer than 48 hours
489 please inform the study personal who will refer you the study physician.

490

491 Other possible risks to you may include: The electrode gel used during
492 electrode placement is slightly abrasive and may cause skin irritation. We
493 encourage participants to inform the researcher of any skin conditions and
494 discomfort during electrode placement.

495

496

497 **Costs**

498

499 You may have costs for participating in this study.

500

501 There will be no study related items or services billed to you or your insurance
502 company. There is no plan to pay you for lost wages, lost time from work,
503 personal discomfort, or for injuries or problems related to your underlying
504 medical condition(s). If you receive a bill that you think is incorrect,
505 please contact the research personnel. You will be responsible to pay for your
506 travel to and from the study site and other out-of-pocket expenses such as
507 parking.

508

Research-Related Injury

509

510 There is a possibility that you could have research-related injury, which is an
511 illness or an injury that is directly caused by the study procedure. If you have
512 a research-related injury, we will offer you reasonable and necessary care to
513 treat injuries directly resulting from taking part in this research. Neither
514 Jefferson nor the study will pay for costs associated with treatment of research-
515 related injury or illness. These costs may be billed to your insurance. In
516 addition, you will be responsible for any deductibles and co-payments required
517 under your health plan and for any claims ultimately denied by your health
518 plan.

519

520

521 There are no plans for Jefferson to pay you or give you other compensation for
522 the injury. However, you are not prevented from seeking to collect
compensation for injury related to malpractice, fault, or blame on the part of

523 those involved in the research. If you think you have been injured as a result
524 of taking part in this research study, tell the research personnel as soon as
525 possible. Please see the contact information in this consent form.

526

527 **Disclosure of Financial Interest**

528

529 There are no conflicts of interest to report in this study.

530

531 **Privacy and Confidentiality: HIPAA Authorization**

532

533 Information will be collected about you for this study. The information will be
534 seen by the people involved with this research. Steps will be taken to protect
535 your identity. But the information collected about you can never be 100%
536 secure.

537

538 **HIPAA (Health Insurance Portability and Accountability Act)** – This is the law
539 that protects your personal health information.

540

541 To do this study, we need to collect, use, and share your personal health
542 information. This form will explain why your information is being collected,
543 what information will be collected, and who will have access to it. By signing,
544 you are giving us permission to use your information as described in this form.

545

546 We are committed to respecting your privacy and to keeping your personal
547 health information confidential. Your personal health information includes the
548 information in your health care records and information that can identify you.
549 For example, personal information may include your name, address, phone
550 number, social security number, and medical information. The personal health
551 information that may be collected, used, and shared for this research includes:

552

- 553 • Information from your medical records
- 554 • Demographic information such as name, gender, birth date, ethnicity,
555 medical history, and health care providers
- 556 • Physical examinations, procedures, tests, labs, your medical conditions,
557 and medications you use
- 558 • Information collected about any research related injury
- 559 • Information about mental health, sexually transmitted diseases, HIV,
560 AIDS, drug and alcohol use, genetic test results, and other sensitive
561 information
- 562 • Biomarker Sampling (blood, saliva)

563

564 Your personal information will be used by and shared with the following:

565

- 566 • Personnel at Thomas Jefferson University and its affiliates for the

567 purpose of this research

568 • Research personnel at Rothman

569 • Institutional Review Boards (ethics committees that review research)

570 including the Thomas Jefferson University IRB

571 • Health insurance providers

572 • Research monitors hired by the sponsor to oversee the study and review

573 health care records to ensure study-related information is correct

574 • Government Agencies like the Food and Drug Administration (FDA)

575 • An organization such as a contract research organization (CRO) that has

576 been hired to coordinate the study

577 • Public health authorities who monitor such things as sexually

578 transmitted diseases, HIV, AIDS, child abuse, as required by law

579 • Groups monitoring the safety of the study such as a data and safety

580 monitoring committee

581 • Others as required by law

582 When your personal information is provided to some of the people listed, it

583 may no longer be protected under the HIPAA privacy law. You can see your

584 health care records at any time. However, generally you will not be able to see

585 your study records or the study results until the study is completed. A copy of

586 this signed form, information about this study, and the results of any study

587 test or procedure may be included in your health records which may be seen

588 by your insurance company and your health care providers.

589

590 This authorization does not have an expiration date. Please inform the

591 investigator in writing if you want to end your permission to collect

592 information/samples. Please note that anything already collected will still be

593 used and you may not be able to continue in this study.

594

595 The information from this study may be published in scientific journals or

596 presented at scientific meetings, but you will not be personally identified.

597

598 A description of this study will be available on <http://www.ClinicalTrials.gov>,

599 as required by U.S. Law. This website will not include information that can

600 identify you. At most, the website will include a summary of the results. You

601 can search this website at any time.

602

603 Your private information and specimens, with the identifiers removed, could

604 be used for future research studies or distributed to other researchers for

605 future research studies without your additional permission.

606

607 **Contacts**

608 **If you are having a medical emergency, call 911 or go directly to an**

609 **emergency room. You should let emergency personnel or providers**

610 **know that you are taking part in this study.**

611
612

For Questions About:	Person or Office	Contact Information
The Study or Research Related Injury	Investigator: Jayakrishnan Nair, PT, PhD Mijail Serruya, MD, PhD Dana R. Johnson, PT, DPT	352-871-5888 215-964-7276 215-868-1988
If you need to contact someone other than the study personnel about a concern or your rights as a research subject	Jefferson Center City Institutional Review Board (Ethics Committee)	215-503-0203 215-503-8966 215-955-4239

613
614

Signatures

Patient/Subject: By signing this form, you are agreeing that:

- You were given the opportunity to read this form.
- All of the information in this form was discussed with you by an investigator or other research personnel to your satisfaction.
- All your questions have been answered to your satisfaction.
- You were not pressured and you voluntarily agree to take part in this research.

Your Name

Your **Signature**

Date

**Name of Person
Obtaining/Assisting
with Consent**

**Signature of Person
Obtaining/Assisting
with Consent**

Date

By signing below, you the **investigator**, certify that you, a co-investigator, or other properly trained and qualified key personnel, reviewed the elements of consent with the study participant.

Name of Investigator

Signature of Investigator

Date

Name of Witness

Signature of Witness

Date

(Witness required if the only language the subject speaks and understands is English, but the subject cannot read English, or if the subject is blind or cannot physically sign the consent form.)

Copy of Signed and Dated Consent Form Given to the Subject/Parent/LAR

655 **Optional Teach-Back Questions** – These questions can be asked to help
656 ensure that the patient understands the study.

657 Check this box if these questions were reviewed with the patient.

658 We have gone over a lot of information. I would like to ask you a few
659 questions to make sure I have done a good job explaining the study to you.

660 1. In your own words, please answer these questions about this study:

661 a. Why are we doing this study (what are we trying to learn)?

662 b. What things (including tests and procedures) will you have to do
663 in this study?

664 c. What are some of the risks of being in this study?

665 d. What is the benefit of being in this study?

666 e. How will being in this study be different than usual medical care?

667 f. How long will you be in this study?

668 2. Taking part in this study is voluntary. What does that mean to you?

669 a. If you don't want to be in this study, what are your other
670 choices?

671 b. What will happen if you chose not to be in this study?

672 3. What will we do to make sure your information remains confidential?

673 4. What other questions do you have about this study?